Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists combination therapy on weight management within a digital-supported shared care model for type 2 diabetes.
GLP-1 receptor agonists just scored another win in real-world data, this time paired with SGLT-2 inhibitors for weight management in people with type 2 diabetes. Researchers at Xi'an Jiaotong University tracked 921 people in a digital-supported shared care clinic for nearly two years. Four groups got compared: SGLT-2i alone, GLP-1RA alone, both together, or neither.
Endocr Pract
by Wang M, Zhang C, Xu J
“Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists combination therapy on weight management within a digital-supported shared care model for type 2 diabetes. Wang M(1), Zhang C(2), Xu J(3). Author information: (1)Department of Endocrinology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710114,China. Electronic address: 13324667966@163.com. (2)Department of Endocrinology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710114,China. Electronic address: zchspring1973@163.com. (3)Department of Endocrinology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710114,China. Electronic address: xujingjdey85@163.com. AIM: To evaluate weight management efficacy of SGLT-2i and GLP-1RA therapy in overweight/obese type 2 diabetes (T2D) patients within a digital shared care model. METHODS: We conducted a real-world retrospective analysis of 921 patients from a diabetes shared care clinic (2022-2025). Patients were stratified into four groups: SGLT-2i, GLP-1RA, combination therapy, and control. Primary outcomes included changes in body weight, BMI, waist circumference, and HbA1c after median 1.84 years of follow-up. Hierarchical multivariable logistic regression adjusted for baseline characteristics and digital engagement metrics. RESULTS: Combination therapy achieved the greatest median weight reduction (5.1%; 4.0 kg). GLP-1RA monotherapy showed the largest HbA1c reduction (-1.20%). After adjusting for digital engagement, the odds of ≥5% weight loss in combination group increased by 5.02%. Higher baseline BMI and longer diabetes duration predicted weight loss success, while higher baseline HbA1c was negatively associated. CONCLUSIONS: SGLT-2i and GLP-1RA combination therapy provides superior weight management in overweight/obese T2D patients, with effects enhanced by digital shared care model. Copyright © 2026 AACE. Published by Elsevier Inc. All rights reserved.”
Combination therapy delivered the biggest median weight drop—5.1% of starting body weight (about 4 kg). GLP-1RA monotherapy still led for HbA1c reduction at -1.20%. The digital support wasn’t just window dressing: adjusting for digital engagement, the odds of dropping at least 5% of body weight jumped more than fivefold with combo therapy compared to controls.
Some quick takeaways:
More baseline body fat and longer diabetes duration made weight loss more likely.
Higher starting HbA1c actually made big weight loss less likely.
Digital monitoring and guidance amped up results, not just the compounds themselves.
Key takeaway: Stacking GLP-1 receptor agonists with SGLT-2 inhibitors, especially with modern digital care, drives substantial weight loss in type 2 diabetes research. The results here add real-world muscle to what controlled trials have shown for peptides targeting metabolism and weight.
If you’re digging into metabolic peptides and their combinations, this study is a prime example of why the research community keeps pushing for smarter protocols and digital tracking. For a broader look at current peptide work, check out the peptide research index. Peptide science keeps moving fast—and the results keep getting more compelling.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.